Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin

Phase 3

• Conditions: Diabetes Mellitus, Type 2
• Interventions: Drug: Janagliflozin plus metformin; Device: Placebo plus metformin

• Registration Number: NCT03851432
• Lead Sponsor: Sihuan Pharmaceutical Holdings Group Ltd.

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of Janagliflozin compared to placebo, both in combination with Metformin, in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with Metformin alone.

Detailed Description

A multicentre, randomized, double-blind, placebo-controlled, parallel-group study (a 24-week core period followed by a 28-week extension period), to evaluate the efficacy and safety of Janagliflozin (25 mg and 50 mg) compared to placebo, all in combination with Metformin, in patients diagnosed with T2DM who are not achieving an adequate response from Metformin monotherapy. Approximately 390 patients with inadequate glycemic control with Metformin monotherapy will receive once-daily double-blind treatment with Janagliflozin 25 mg or 50 mg , both in combination with Metformin , for 52 weeks, or receive 24 weeks of double-blind treatment with placebo in combination with Metformin followed by 28 weeks of single-blind treatment with Janagliflozin 25 mg or 50 mg, both in combination with Metformin. During the treatment, if a patient's glycemic level remains high despite treatment with study drug and reinforcement with diet and exercise, the patient will receive treatment with Linagliptin (rescue therapy) consistent with local prescribing information.

Study Timeline

• Study First Submitted: 2019-02-20
• Study First Submitted QC: 2019-02-20
• Study First Posted: 2019-02-22
• Study Start: 2019-06-30
• Primary Completion: 2020-04-30
• Status Verified: 2020-07
• Last Update Submitted: 2020-07-14
• Last Update Posted: 2020-07-16
• Study Completion: 2021-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 390

Inclusion Criteria

• T2DM Patients with inadequate glycemic control (HbA1c level≥7.0% and ≤10.5% at baseline) on metformin monotherapy.
• Body Mass Index: 18.0~35.0 kg/m2 (both inclusive)

Read More

Exclusion Criteria

• History of type 1 diabetes mellitus (T1DM), diabetes caused by pancreatic injury, or secondary diabetes (e.g., diabetes caused by Cushing's syndrome or acromegaly)

• More than 10% change in body weight within the 3 months before screening

• Any laboratory test indicators meet the following standards:

  • fasting plasma glucose ≥ 15 mmol/L
  • aspartate aminotransferase, alanine aminotransferase levels > 3 times the upper limit of normal (ULN); total bilirubin > 1.5 times ULN
  • hemoglobin < 100 g/L
  • eGFR < 60 mL/min/1.73m2
  • fasting triglycerides > 5.64 mmol/L (500 mg/dL)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Janagliflozin 50 mg plus metformin	Janagliflozin plus metformin	Each patient will receive 50 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
Janagliflozin 25 mg plus metformin	Janagliflozin plus metformin	Each patient will receive 25 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
Placebo/Janagliflozin plus metformin	Placebo plus metformin	In the core period, each patient will receive placebo plus metformin for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin plus metformin until Week 52.

Primary Outcome Measures

Name	Time	Method
Change in Hemoglobin A1c (HbA1c) From Baseline to Week 24 (Core period)	Baseline and Week 24	To examine whether the mean change in HbA1c from Baseline to Week 24 with Janagliflozin is superior to placebo

Secondary Outcome Measures

Name	Time	Method
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24 (Core period) and Week 52 (Extension period)	Baseline, Week 24 and Week 52	To compare the mean change in fasting plasma glucose (FPG) from Baseline to Week 24 (core period) and Week 52 (extension period) between groups
Change in 2-hour Post-prandial Glucose From Baseline to Week 24 (Core period) and Week 52 (Extension period)	Baseline, Week 24 and Week 52	To compare the mean change in 2-hour post-prandial glucose from Baseline to Week 24 (core period) and Week 52 (extension period) between groups
Change in Body Weight From Baseline to Week 24 (Core period) and Week 52 (Extension period)	Baseline, Week 24 and Week 52	To compare the mean change in body weight from Baseline to Week 24 (core period) and Week 52 (extension period) between groups
Change in Fasting C-peptide From Baseline to Week 24 (Core period) and Week 52 (Extension period)	Baseline, Week 24 and Week 52	To compare the mean change in fasting C-peptide from Baseline to Week 24 (core period) and Week 52 (extension period) between groups
Change in HbA1c From Baseline to Week 52	Baseline and Week 52	To compare the mean change in HbA1c from Baseline to Week 52 between groups
Percentage of Patients With HbA1c <6.5% at Week 24 (Core period) and Week 52 (Extension period)	Baseline, Week 24 and Week 52	To compare the percentage of patients with HbA1c \<6.5% at week 24 (core period) and Week 52 (extension period) between groups
Change in Blood Lipids (total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) From Baseline to Week 24 (Core period) and Week 52 (Extension period)	Baseline, Week 24 and Week 52	To compare the mean change in blood lipids (total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) from Baseline to Week 24 (core period) and Week 52 (extension period) between groups
Change in Blood Pressure (systolic blood pressure and diastolic blood pressure) From Baseline to Week 24 (Core period) and Week 52 (Extension period)	Baseline, Week 24 and Week 52	To compare the mean change in blood pressure (systolic blood pressure and diastolic blood pressure) from Baseline to Week 24 (core period) and Week 52 (extension period) between groups
Change in Insulin Sensitivity From Baseline to Week 24 (Core period) and Week 52 (Extension period) by calculation Homeostasis model assessment-insulin resistance	Baseline, Week 24 and Week 52	To compare the mean change in insulin sensitivity from Baseline to Week 24 (core period) and Week 52 (extension period) between group by calculation Homeostasis model assessment-insulin resistance
Percentage of Patients With HbA1c <7% at Week 24 (Core period) and Week 52 (Extension period)	Week 24 and week 52	To compare the percentage of patients with HbA1c \<7% at Week 24 (core period) and Week 52 (extension period) between groups
Percentage of Patients Who Have Received Rescue Therapy at Week 24 (Core period) and Week 52 (Extension period)	Baseline, Week 24 and Week 52	To compare the percentage of patients who have received rescue therapy by Week 24 (core period) and Week 52 (extension period) between groups.
Change in β-cell Function From Baseline to Week 24 (Core period) and Week 52 (Extension period)	Baseline, Week 24 and Week 52	To compare the mean change in β-cell function from Baseline to Week 24 (core period) and Week 52 (extension period) between groups

Trial Locations

Locations (1)

Linong Ji; 🇨🇳 Beijing, Beijing, China